AstraZeneca is set to make one of its first acquisitions in China, announcing plans to acquire Gracell Biotechnologies for up to $1.2bn to increase its investment in cell therapies for treating cancer.
阿斯利康(AstraZeneca)将进行其在manbetx3.0 的首批收购之一，宣布计划以最高12亿美元收购亘喜生物(Gracell Biotechnologies)，以增加其在癌症细胞疗法领域的投资。
您已阅读7%（294字），剩余93%（3661字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。